SCHEMBL30764749

SCHEMBL30764749

O=C(Cc1ccc(Cl)cc1)N1CC2(CN(CCc3ccccc3Cl)C2)C1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.49
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
GFER P55789 1/20 0.45
ATM Q13315 1/20 0.45
KCNH2 Q12809 1/20 0.45
GPR183 P32249 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
SIGMAR1 Q99720 1/20 0.39
ME2 P23368 1/20 0.39
ME1 P48163 1/20 0.39
ME3 Q16798 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30764756 0.91 HSD11B1 (0.47) HSD11B1KMT2AMEN1KCNH2TP53
SCHEMBL30764724 0.81 HSD11B1 (0.51) HSD11B1KMT2AMEN1GFERATM
SCHEMBL30764734 0.81 KMT2A (0.54) HSD11B1KMT2AMEN1GFERATM
SCHEMBL30764707 0.80 HSD11B1 (0.55) HSD11B1KMT2AMEN1GFERATM
SCHEMBL30764745 0.80 SIGMAR1 (0.53) HSD11B1KMT2AMEN1KCNH2CYP2C19
SCHEMBL30764764 0.79 ALDH1A1 (0.49) HSD11B1TP53MAPTSIGMAR1
SCHEMBL30764754 0.79 HSD11B1 (0.46) HSD11B1KMT2AMEN1GFERATM
SCHEMBL30764719 0.78 SMN1; SMN2 (0.53) HSD11B1MAPTSIGMAR1
SCHEMBL30764710 0.77 HSD11B1 (0.45) HSD11B1KMT2AGFERATMKCNH2
SCHEMBL30764731 0.74 HSD11B1 (0.56) HSD11B1KMT2AMEN1KCNH2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568968-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Remynd N.V. (BE) 2025-06-18 EP disclosed
WO-2024033479-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2024-02-15 WO disclosed